Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.

TitleTumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.
Publication TypeJournal Article
Year of Publication2016
AuthorsOudin, MJ, Jonas, O, Kosciuk, T, Broye, LC, Guido, BC, Wyckoff, J, Riquelme, D, Lamar, JM, Asokan, SB, Whittaker, C, Ma, D, Langer, R, Cima, MJ, Wisinski, KB, Hynes, RO, Lauffenburger, DA, Keely, PJ, Bear, JE, Gertler, FB
JournalCancer Discov
Volume6
Issue5
Pagination516-31
Date Published2016 May
ISSN2159-8290
Abstract

UNLABELLED: Fibronectin (FN) is a major component of the tumor microenvironment, but its role in promoting metastasis is incompletely understood. Here, we show that FN gradients elicit directional movement of breast cancer cells, in vitro and in vivo Haptotaxis on FN gradients requires direct interaction between α5β1 integrin and MENA, an actin regulator, and involves increases in focal complex signaling and tumor cell-mediated extracellular matrix (ECM) remodeling. Compared with MENA, higher levels of the prometastatic MENA(INV) isoform associate with α5, which enables 3-D haptotaxis of tumor cells toward the high FN concentrations typically present in perivascular space and in the periphery of breast tumor tissue. MENA(INV) and FN levels were correlated in two breast cancer cohorts, and high levels of MENA(INV) were significantly associated with increased tumor recurrence as well as decreased patient survival. Our results identify a novel tumor cell-intrinsic mechanism that promotes metastasis through ECM remodeling and ECM-guided directional migration.SIGNIFICANCE: Here, we provide new insight into how tumor cell:ECM interactions generate signals and structures that promote directed tumor cell migration, a critical component of metastasis. Our results identify a tumor cell-intrinsic mechanism driven by the actin regulatory protein MENA that promotes ECM remodeling and haptotaxis along FN gradients. Cancer Discov; 6(5); 516-31. ©2016 AACR.See related commentary by Santiago-Medina and Yang, p. 474This article is highlighted in the In This Issue feature, p. 461.

DOI10.1158/2159-8290.CD-15-1183
Alternate JournalCancer Discov
PubMed ID26811325
PubMed Central IDPMC4854754
Grant ListP30 CA014051 / CA / NCI NIH HHS / United States
R01 CA114462 / CA / NCI NIH HHS / United States
R01 CA142833 / CA / NCI NIH HHS / United States
U01 CA143069 / CA / NCI NIH HHS / United States
U01 CA184897 / CA / NCI NIH HHS / United States
U54 CA112967 / CA / NCI NIH HHS / United States